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Background: Alcohol-related cerebellar degeneration is one of the commonest acquired forms of cerebellar ataxia.
The exact pathogenic mechanisms by which alcohol leads to cerebellar damage remain unknown. Possible
autoreactive immune mediated mechanisms have not been explored previously. In this study, we aim to
investigate the potential role of alcohol-induced immune mediated cerebellar degeneration.
Methods: Patients with ataxia and a history of alcohol misuse were recruited from the Ataxia and Hepatology
tertiary clinics at Sheffield Teaching Hospitals NHS Trust. We determined the pattern of cerebellar involvement
both on clinical (SARA score) and imaging (MRI volumetry and MR spectroscopy) parameters. In addition, HLA
genotyping, serological markers for gluten-related disorders and serological reactivity on rat cerebellar tissue
using indirect immunohistochemistry were assessed.
Results: Thirty-eight patients were included in the study all of whom had ataxia. The gait (97 %), stance (89 %)
and heel-shin slide (89 %) were the predominant SARA elements affected. MRI volumetric and spectroscopy
techniques demonstrated significant structural, volumetric and functional deficits of the cerebellum with particular
involvement of the cerebellar vermis. Circulating anti-gliadin antibodies were detected in 34 % patients vs. 12 % in
healthy controls. Antibodies to transglutaminase 6 (TG6) were detected in 39 % of patients and 4 % of healthy control
subjects. Using immunohistochemistry, Purkinje cell and/or granular layer reactivity was demonstrated in 71 % of
patient sera.
Conclusions: Alcohol induced tissue injury to the CNS leading to cerebellar degeneration may also involve immune
mediated mechanisms, including sensitisation to gluten.
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Alcohol misuse is recognized worldwide as a major
cause of morbidity and mortality with significant health
and economic consequences. The toxic effects of alcohol
are diverse. Alcohol-related cerebellar degeneration is
one of the commonest causes of acquired cerebellar
ataxia. The pathophysiology remains unclear but pro-
posed mechanisms include excitotoxicity, dietary factors,
oxidative stress, compromised energy production and
cell death [1]. Some argue that the direct toxic effects of
alcohol on cerebellar cells is responsible, whilst others* Correspondence: p.d.shanmugarajah@sheffield.ac.uk
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Cerebellar atrophy is a recognised result of alcohol-
related cerebellar degeneration. The anterior superior
cerebellar vermis is predominantly affected [3, 4] with
the Purkinje cell, granular and white matter layers being
most susceptible [2]. This has been confirmed in large
autopsy studies [5, 6]. MRI findings of vermian atrophy,
with preferential involvement of the lingula [7], are in
keeping with the neuropathological findings.
Metabolic deficits can be demonstrated by magnetic
resonance (MR) spectroscopy, with low N-acetyl asparta-
te:creatine ratio (NAA/Cr) in the cerebellar vermis. MR
Spectroscopy can directly detect ethanol by a triple peak
at 1.3 ppm [8]. Chronic alcohol use causes a reduction inle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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Shanmugarajah et al. Cerebellum & Ataxias  (2016) 3:17 Page 2 of 7NAA and choline levels compared to healthy controls;
thus MR spectroscopy provides a useful tool for monitor-
ing cerebellar function.
Chronic alcohol use has been shown to provoke an
IgA response that is not only directed towards alcohol
metabolites but also against self antigens, targeting the
enzyme transglutaminase 2 (TG2), even in the absence
of liver disease [9]. Transglutaminases are a widely dis-
tributed family of enzymes with cross-linking capability
that aid tissue repair [10]. TG2 is the autoantigen in
coeliac disease. However, autoimmunity to TG2 can
also precipitate hepatitis and ultimately liver failure
[11]. Proposed mechanisms for the high prevalence of
TG2 autoantibodies in patients with chronic alcohol
abuse include increased gut permeability associated with
alcohol induced intestinal mucosal lesions [9] leading to
increased exposure of the immune system to pathogenic
antigens (including gluten peptides). In line with this, alco-
hol has been shown to induce sensitisation to gluten in
genetically susceptible individuals [12].
The aim of this study was to investigate further a po-
tential link between autoreactive immune responses
and cerebellar degeneration in the context of excessive
alcohol intake.
Methods
Subject selection and clinical assessments
The study was approved by the regional ethics commit-
tee (Yorkshire & The Humber, UK). Written informed
consent was obtained from all patients. Patients were re-
cruited from the Ataxia and Hepatology outpatient
clinics at the Royal Hallamshire Hospital, Sheffield, UK.
Patients included were grouped as ‘alcohol ataxia (AA)’
and had a history of chronic ‘alcohol dependence’, defined
by the 4th edition of the Diagnostic and Statistical Manual
of Mental Disorders (DSM-IV) Diagnostic Criteria for Al-
cohol Abuse and Dependence [13]. A subgroup of patients
with alcohol-related ‘chronic liver disease’ (defined as alco-
hol related liver disease diagnosed by a hepatologist and
disease present for more than 1 year) and ataxia (CLDA)
was identified from this patient group.
Detailed neurological history and any background his-
tory of autoimmune disorders were recorded, as were age
at onset, duration of ataxia, requirement for mobility aids,
and current alcohol intake or abstinence at the time of
recruitment.
Detailed neurological examination was performed. Ataxia
was classified as gait, limb or both and severity was assessed
as mild (mobilising independently or with one walking aid),
moderate (mobilising with 2 walking aids or walking frame)
or severe (wheelchair-dependent). The severity assessment
was adapted and modified from previously published data
[14]. Objective measurement of the severity of ataxia was
rated using the Scale for the Assessment and Rating ofAtaxia (SARA) [15, 16] (see Additional file 1). All patients
were investigated for other causes of ataxia and were ex-
cluded if an alternative cause was found. Tests depending
on clinical indications included blood cell counts, biochem-
istry, thyroid function, B12, folate and genetic testing for
inherited spinocerebellar ataxias (SCA 1, 2, 3, 6, 7) and
Friedreich’s ataxia (FA).Brain imaging
Volumetric 3T MR imaging and single-voxel H1 MR
spectroscopy of the cerebellum were undertaken in patients
with clinical evidence of ataxia. This imaging protocol is in
clinical use as part of the investigations of all patients with
cerebellar ataxia who attend the National Ataxia Centre in
the Royal Hallamshire Hospital, Sheffield, UK. The brain
imaging protocol for structural, volumetric and spectros-
copy studies have been previously reported [12].
The vermis was assessed as a whole for volumetric
analysis. A manual approach was adopted for volumetric
analysis of the vermis to avoid partial volume averaging
effects that may also be affected by the degree of atrophy
potentially confounding VBM results (unpublished data).
For vermian volumetric studies, the midline vermis was
identified on sagittal T1 volume images with reference
to the midsagittal plane of the cerebellum [17]. Based on
this reference, manual measurement of cross sectional
areas of the whole vermis was possible. Vermian volume
(V) in mm3 was measured as a sum of vermis cross sec-
tional areas (mm2) multiplied by 0.9 mm thickness. Ver-
mian volume was expressed as a percentage of the total
intracranial volume (%V:TIV).
Healthy controls recruited, were age and gender matched
with patient subjects and had undergone the same MR
imaging protocol. The details of the healthy controls
have also been previously reported [18].Blood collection and serological tests
Blood samples were collected at recruitment and the
serum was aliquoted to avoid repeat freeze-thawing and
stored at −20 ° C in sealed tubes.
All patients had total immunoglobulin levels, IgA and
IgG anti-gliadin antibodies (AGA), anti-endomysial anti-
bodies (EMA) and IgA anti-transglutaminase 2 (TG2)
antibodies, measured by standard laboratory protocols at
the Immunology Department, Northern General Hospital,
Sheffield. Briefly, the measurement for AGA and TG2
were performed by enzyme linked immunosorbent assay
(ELISA) (Aesku. Diagnostics-Grifols, Germany). EMA was
tested by indirect immunofluorescence on slides contain-
ing monkey oesophagus tissue (Inova-Instrumentation
Laboratories, USA). Patient sera were also used for the
detection of IgA and IgG to transglutaminase 6 (TG6)
by ELISA as previously described [19].
Table 1 Scale for the assessment and rating of ataxia (SARA) in
patients with alcohol ataxia
SARA elements AA CLDA Total
Gait 29/30 (97 %) 8/8 (100 %) 37/38 (97 %)
Stance 26/30 (87 %) 8/8 (100 %) 34/38 (89 %)
Sitting 5/30 (17 %) 0/8 (0 %) 5/38 (13 %)
Speech disturbance 10/30 (33 %) 1/8 (13 %) 11/38 (29 %)
Finger chase 15/30 (50 %) 5/8 (63 %) 20/38 (53 %)
Nose-finger test 17/30 (57 %) 5/8 (63 %) 22/38 (58 %)
Fast alternating hand
movements
18/30 (60 %) 6/8 (75 %) 24/38 (63 %)
Heel-shin slide 27/30 (90 %) 7/8 (88 %) 34/38 (89 %)
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formed at the National Blood Service, Sheffield, UK.
Immunohistochemistry
Rat cerebellar tissue was acquired from adult Sprague-
Dawley rats (Biological Services, Faculty of Medicine,
Dentistry & Health, University of Sheffield). The cerebellar
tissue was mounted using Cryo-M-Bed tissue embedding
polymer (Bright, UK) and snap-frozen with isopentane/
cooled on liquid nitrogen. The cerebellar tissue was cryo-
sectioned into 10 μm sagittal sections that were collected
on polysine-coated slides (Thermo Scientific, UK), stored
at −80 ° C in an airtight container.
Mouse anti-calbindin-D-28K monoclonal antibody
(Sigma, UK) diluted 1:200 in PBS was used to visualize
Purkinje cells. Patient sera were diluted 1:200 or 1:600 in
PBS before incubation with sections for 1 h. 1:600 was
identified as the optimum dilution in determining the
reactivity of patient sera on rat cerebellar tissue in
agreement with our previous study [20]. Negative controls
included sections incubated without patient sera. A
horseradish peroxidase-conjugated goat anti-human or goat
anti-mouse IgG antibody (Jackson ImmunoResearch La-
boratories, USA) was used as secondary antibodies.
Images were captured at X100 and X200 magnifica-
tion. Two blinded observers performed the evaluation of
the Purkinje cell staining intensity on rat cerebellar sec-
tions independently. Staining was classed as ‘weak’ or
‘strong’ if Purkinje cell staining was above background
levels. ‘Negative’ was recorded if staining did not exceed
background levels. Staining of other neuronal cell popu-
lations (granular layer) was also noted. Concordance rate
between assessors was 79 %.
Statistical analysis
Statistical analysis was performed using PRISM 6 soft-
ware package (GraphPad Software Inc.). Demographic,
clinical and imaging characteristics are presented as
means with standard deviations (mean ± SD). The
Independent-Samples Mann-Whitney U Test was used
to determine any difference between mean % cerebellar
volume (CBV) : total intracranial volume (TIV) and
mean % vermian volume (V) : total intracranial volume
(TIV) between patients and controls. The χ2 test was
used for comparing the prevalence of anti-gliadin anti-
bodies and anti-transglutaminase 6 antibodies in the
study group with that of the healthy population; and
between the subgroups. Results were considered statis-
tically significant for p < 0.05.
Results
Clinical presentation
Thirty-eight patients were recruited with mean age of
54 ± 10 years. There were 31 male and 7 female patients.All patients had clinical evidence of ataxia. Thirty of the
38 (79 %) patients were grouped as ‘alcohol ataxia’ (AA)
as ataxia was their presenting complaint. A further
group of 8/38 (21 %) patients recruited from the Hepa-
tology clinics, were selected on the basis of having
alcohol-related chronic liver disease, but were also found
to have ataxia, hence categorised as ‘chronic liver disease
and ataxia’ (CLDA). Fourteen patients (37 %) had been
abstinent from alcohol consumption at the time of recruit-
ment. A background of autoimmune history (diabetes (2),
thyroid disorder (1), pernicious anaemia (4)) was seen in
7/38 (18 %) patients.
Age of ataxia onset was 49 ± 11 years. Duration of ataxia
ranged from one to 27 years (Mean 6 ± 5 years). Pure gait
ataxia was found in 4/38 (11 %) patients and the majority
of 34/38 (89 %) patients had both gait and limb ataxia.
Nystagmus was present in 11/38 (29 %) patients.
Forty seven percent had mild ataxia (mobilising inde-
pendently or with one walking aid). Moderate ataxia was
seen in 34 % and severe ataxia was seen in 18 % patients.
There was no difference in the autoimmune profile be-
tween patients with mild, moderate or severe ataxia. The
severity of ataxia using the SARA scale revealed a mean
total SARA score of 12 ± 7 (range 1 to 26). There was a
correlation seen between duration of ataxia and total
SARA score (p 0.0272).
Table 1 demonstrates the frequency of involvement for
each of the eight key SARA elements. The gait (97 %),
stance (89 %) and heel-shin slide (89 %) were the pre-
dominant SARA elements affected.
Brain imaging
MR Spectroscopy was performed in 34 patients. Data
analysis was based on 32 (25 AA and 7 CLDA) optimal
scans. Two scans were excluded as they were of inadequate
quality. Abnormal NAA/Cr area ratio (vermis NAA/Cr
< 0.95 and/or hemisphere NAA/Cr < 1.00) [21] was
recorded in 29/32 (91 %) patients. This included 22/25
(88 %) patients with AA and 7/7 (100 %) patients with
CLDA.
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18/25 (72 %) patients with AA and 6/7 (86 %) patients
with CLDA. The hemisphere was solely affected in only
4/25 (16 %) patients with AA and 1/7 (14 %) patients
with CLDA.
Volumetric Image analysis matched for age and gender
with healthy controls was possible in 28 patients (22 pa-
tients with AA and six patients with CLDA). Results are
displayed as a whole group (AA and CLDA) vs. controls.
Cerebellar volume (%CBV:TIV) was significantly smaller
(8.68 ± 0.99) in this study group when compared with
age and gender matched healthy controls (9.57 ± 0.96);
CI 95 % 8.29 to 9.06, p 0.0027. Similarly, vermian volume
(%V:TIV) was significantly smaller in the study group
(1.13 ± 0.24) when compared to age and gender matched
healthy controls (1.34 ± 0.13); CI 95 % 1.03 to 1.22, p
0.0003.
There was no significant correlation seen between
total SARA score and brain imaging measures.
Serological testing for gluten-related antibodies
Normal total serum immunoglobulins were seen in 21/
38 (55 %) patients. Raised IgA levels were seen in 8/38
(21 %) patients.
Circulating anti-gliadin antibodies were detected in 13/38
(34 %) patients (8 AA and 5 CLDA) compared with a 12 %
prevalence in healthy controls [22] (χ2 p 0.012). The
difference between the AA and CLDA groups was not
statistically significant. Circulating anti-transglutaminase 2
(TG2) antibodies were demonstrated in 4/38 (11 %) pa-
tients, (3 AA and 1 CLDA). The three AA patients had low
TG2 antibody titres and the one CLDA patient had TG2
antibody titres >300 U/mL. No patients tested positive for
EMA.
Antibodies to transglutaminase 6 (TG6) were detected
in 15/38 (39 %) patients vs. 4 % in healthy controls [23]
(χ2 p <0.0001). The 15 patients with anti-TG6 antibodies
included 9/30 (30 %) patients with AA and 6/8 (75 %)
patients with CLDA (χ2 p 0.0207). Thirteen of the 15
patients had IgA anti-TG6 antibodies, one had IgG
anti-TG6 antibodies and one patient had both IgA and
IgG anti-TG6 antibodies.
HLA genotyping for DQ2/DQ8
Eighteen of the 38 (47 %) patients in the study group
had HLA type DQ2 or DQ8. This was not significantly
different from the healthy population of 30 % [24]
(p 0.056). There was no significant difference be-
tween any subgroup (AA vs. CLDA), using the χ2 test.
Serum reactivity with neural tissue
Three specific staining patterns were identified (pure
Purkinje cell, pure granular layer and combined Purkinje
cell and granular layer staining pattern) when rat brainsections were incubated with patient sera (see Additional
file 2). In 27/38 (71 %) patients, one of these patterns
was present.
Pure Purkinje cell (PC) staining was demonstrated in
4/38 (11 %) patients. This included 3/30 (10 %) patients
with AA and 1/8 (13 %) patients with CLDA. Pure
granular layer staining was demonstrated in 16/38
(42 %) patients. This included 12/30 (40 %) patients
with AA and 4/8 (50 %) patients with CLDA. Combined
Purkinje cell and granular layer staining was demonstrated
in 7/38 (18 %) patients that included 5/30 (17 %) patients
with AA and 2/8 (25 %) patients with CLDA.
Overall, Purkinje cell reactivity was seen in 11/38
(29 %) of patients and granular layer reactivity in 23/38
(61 %) patients. There was no statistically significant dif-
ference in prevalence of Purkinje cell and/or granular
layer staining between the 2 subgroups.
Based on the same methodology, our previous studies
did not demonstrate any staining in healthy controls and
showed only 5 % staining in patients with genetic ataxia
[20, 25]. Table 2. summarises the serological characteris-
tics of patients with alcohol ataxia.Discussion
In this study, we investigated whether an autoimmune
process may drive alcohol-induced cerebellar damage.
Our initial intention was to study patients with alcoholic
liver disease without ataxia and a subgroup of patients
who presented with alcohol-induced ataxia. However, all
patients with alcoholic liver disease were found to also
have ataxia thus a subgroup of patients with ‘chronic
liver disease and ataxia’ was defined. This division into 2
subgroups is somewhat arbitrary as patients with alcohol-
induced ataxia almost always have some degree of liver in-
volvement (demonstrated by elevated levels of gamma GT).
Given the overlap in functional deficits, our sample size
would also be too small to make any definitive conclusions
on specific differences between the 2 subgroups. Nonethe-
less, we still studied the 2 subgroups given the distinct
differences in presentation.
Imaging data using MRI volumetric and spectroscopy
techniques demonstrated significant structural and
functional deficits of the cerebellum, with preferential
involvement of the cerebellar vermis. There was sig-
nificant vermian volume loss in patients with alcohol
ataxia compared to age and gender matched healthy
controls. The findings support neuropathological data
that alcohol-related cerebellar degeneration preferentially
affects the cerebellar vermis [2–7]. Vermian involvement
is common in immune-mediated ataxias such as gluten
ataxia, paraneoplastic cerebellar degeneration and primary
autoimmune cerebellar ataxia [26]. We did not find
any correlation between the imaging findings and
Table 2 Serological characteristics of patients with alcohol ataxia
Patient ID Gender Age at study, y HLA DQ2/DQ8 Antigliadin IgA and/or IgG Anti-TG6 IgA and/or IgG PC stained GL stained
8 M 33 DQ2 IgA +
9a M 41 +
20 M 50 DQ8 + ++
27 M 67 ++
28 M 56 IgA + +
30a M 46 +
31 M 50 ++ +
32 M 66 IgA ++ +
33 M 58 DQ8
37 M 53 DQ2 IgA +
38 F 56 IgA +
45 M 49 DQ8 +
47 F 60 IgA
49a M 51 DQ8 IgA, IgG IgA
55 F 48 DQ2 +
62 M 41
69 M 58
92 M 64 DQ8 ++ +
100 M 55 DQ2 IgA
101 F 49 DQ2 +
103 F 48 DQ8 IgA +
104 M 55 DQ2 +
107a M 46 DQ2 IgA IgA ++ ++
116 M 51 DQ8 IgG ++
119 M 48 IgA ++
120a M 50 IgA +
121 M 45 +
122a M 50 IgA IgA +
125 F 66 DQ2 IgA
128 M 68 DQ2 IgA
132 M 62
133a M 59 DQ2 IgA IgA + ++
134 F 58 +
135 M 57 IgA IgA +
136a M 47 IgA IgA +
139 M 65 DQ2 IgA, IgG IgA, IgG
143 M 67 IgG
145 M 81 +
asubgroup chronic liver disease and ataxia (CLDA), y years, TG6 transglutaminase 6, PC Purkinje cell layer, GL granular layer, + weak staining, ++ strong staining
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size, however, may be a contributory factor to this.
Alcohol excess is associated with impairment of the
blood-brain barrier. The oxidative stress caused by alco-
hol metabolism on brain microvascular endothelial cells
by activation of myosin light chain kinase leads todisruption of the tight junctions inducing blood-brain
barrier breakdown [27, 28]. This enhanced permeability
may lead to neo-epitope exposure to the immune system
and thereby induction of autoimmune responses to these
neo-epitopes or allow reaction of serum antibodies
with neural tissue and consequently trigger localized
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we show that 71 % of patients with alcohol ataxia have
circulating antibodies that react with neural tissue.
Three cerebellar staining patterns were seen when rat
brain sections were incubated with patient sera: pure
Purkinje cell (11 %), pure granular layer (42 %) and
combined Purkinje cell and granular layer (18 %). We
have previously shown that up to 60 % of patients with
idiopathic sporadic ataxia have anti-cerebellar anti-
bodies as opposed to 5 % of patients with genetic
ataxia [25]. It is possible that alcohol is a contributing
factor to “idiopathic” sporadic ataxia, or that similar
immune-mediated processes can be triggered by infection
or other unrelated environmental factors in addition to
alcohol.
Increased gut permeability and mucosal damage are
typical clinical findings in patients with alcohol misuse.
Not surprisingly, this may trigger a breakdown in im-
mune tolerance and autoimmune responses in patients
harbouring genetic susceptibility (HLA DQ2/DQ8). Ex-
cessive alcohol intake is a risk factor for coeliac disease
development [9, 12]. TG2 IgA autoantibody titres have
been reported to positively correlate with liver disease
[9] which is in accordance with the view that liver dis-
ease per se may be associated with the occurrence of
TG2 autoantibodies [11]. The role of TG in tissue repair
and its deposition into the extracellular matrix [29] may
lead to abundant autoantibody binding and thereby drive
chronic inflammation and fibrogenesis. Only one of the
patients examined here had high levels of circulating
anti-TG2 autoantibodies suggesting that coeliac disease
is not a primary underlying mechanism in this cohort
selected on the basis of neurological deficits. However,
in gluten-related disorders with extraintestinal manifest-
ation, particularly neurological, enteropathy may not be
present and autoantibodies to TG2 may not be detect-
able in the circulation [19, 23].
It is therefore of interest that firstly, we found a signifi-
cantly higher prevalence of anti-gliadin antibodies in the
study group (34 %) compared to healthy controls (12 %)
and secondly that we found a significantly higher preva-
lence of anti-TG6 antibodies in the study group (39 %)
compared to healthy control subjects (4 %). Circulating
anti-TG6 antibodies are the best marker currently avail-
able for patients with primarily neurological presentation
of gluten-related disorders [23]. However, their preva-
lence in the study group was not substantially different
to what we previously reported for idiopathic ataxia
(32 %), and the association of AGA and anti-TG6 auto-
antibodies is in line with previous findings (gluten ataxia)
[23]. Clearly, these antibodies alone cannot explain the
serum reactivity to the granular layer neurons in most of
these patients [20, 30]. Anti-TG6 antibodies were more
prevalent in the subgroup of patients with CLDA (75 %)compared to the subgroup of patients with AA (30 %) sug-
gesting that alcohol-related chronic liver disease itself may
be another risk factor for the development of autoimmun-
ity to TG6. It remains to be shown where the immune re-
sponse to TG6 develops. The fact that almost exclusively
an IgA response was seen makes the gastrointestinal tract
a likely candidate.
Conclusions
Taken together, these results suggest that factors other
than direct cellular toxicity from alcohol, including
autoimmune responses, may play a part in cerebellar
degeneration in patients with alcohol ataxia. The role
of gluten sensitivity merits further exploration but the
findings of this and previous studies suggest that sensitiv-
ity to gluten may be an epiphenomenon, likely resulting
from increased gut permeability. Development of gluten-
related autoantibodies, however, may perpetuate cerebellar
degeneration even when the patient abstains from alcohol
intake. If that proves to be the case, a gluten free diet may
prove to be beneficial for such patients.
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